RFT1-CDG
R-F-T-one C-D-G
Also known as: Congenital Disorder of Glycosylation Type In, CDG-In
At a Glance
What is RFT1-CDG?
RFT1-CDG is a rare genetic disorder that affects the body's ability to properly glycosylate proteins, a critical process for normal cellular function. This condition primarily impacts the neurological and metabolic systems, leading to developmental delays and other systemic issues. It is caused by mutations in the RFT1 gene, which disrupts the synthesis of glycoproteins. Over time, individuals may experience worsening symptoms, including motor and cognitive impairments. Early symptoms often include hypotonia and feeding difficulties, while later symptoms can involve more severe developmental and neurological challenges. Early diagnosis is crucial as it allows for better management of symptoms and can improve quality of life. The disorder can significantly impact family life, requiring ongoing medical care and support. Prognosis varies, but many individuals face lifelong challenges. Daily life for affected individuals often involves specialized therapies and interventions to manage symptoms. Families may need to adapt their routines to accommodate medical appointments and therapies. Support from healthcare professionals and community resources can be vital in managing the condition. Despite the challenges, early intervention and supportive care can help maximize developmental potential.
Medical Definition
RFT1-CDG is a congenital disorder of glycosylation caused by mutations in the RFT1 gene, leading to defective glycoprotein synthesis. Pathologically, it is characterized by incomplete glycosylation of proteins, which can be observed histologically as abnormal glycan structures. This disorder is classified under CDG type I disorders, specifically affecting the lipid-linked oligosaccharide pathway. Epidemiologically, it is an ultra-rare condition with a prevalence estimated at 1 in 1,000,000. The disease course is progressive, with symptoms often worsening over time. Management focuses on symptomatic treatment and supportive care to improve quality of life.
RFT1-CDG Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Developmental delay in RFT1-CDG manifests as a significant lag in reaching milestones such as sitting, walking, and talking. This is primarily due to impaired glycosylation affecting neural development and function. Over time, the delay may become more pronounced, with some individuals requiring lifelong support. Daily life is impacted as patients may need assistance with basic activities, and early intervention therapies can help improve skills.
Hypotonia presents as decreased muscle tone, making the muscles appear floppy and weak. It results from defective glycosylation affecting muscle and nerve function. As the child grows, hypotonia may lead to challenges in mobility and posture. Physical therapy can help improve muscle strength and coordination, aiding in daily activities.
Failure to thrive is observed as poor weight gain and growth in infants and children with RFT1-CDG. It is caused by metabolic imbalances and nutritional deficiencies due to impaired glycosylation. Over time, this can lead to stunted growth and developmental issues. Nutritional support and monitoring are crucial to manage this symptom and promote healthy growth.
Common
Seizures in RFT1-CDG can vary from mild to severe and may include different types such as tonic-clonic or absence seizures. They occur due to abnormal electrical activity in the brain, linked to glycosylation defects. Seizure frequency and severity can change over time, sometimes becoming more manageable with treatment. Antiepileptic medications and regular monitoring can help control seizures and improve quality of life.
Hearing loss in RFT1-CDG may range from mild to profound and can affect one or both ears. It is associated with structural abnormalities in the ear or neural pathways due to glycosylation defects. Over time, hearing loss can impact speech and language development, especially in children. Hearing aids and early intervention programs can help mitigate these effects and support communication skills.
Liver dysfunction in RFT1-CDG can manifest as elevated liver enzymes, jaundice, or hepatomegaly. This occurs due to abnormal glycosylation affecting liver cells and function. Over time, liver problems can lead to complications such as fibrosis or cirrhosis if not managed. Regular monitoring and supportive treatments can help manage liver health and prevent further damage.
Less Common
Cardiac anomalies in RFT1-CDG may include structural defects such as septal defects or valve abnormalities. These arise from impaired glycosylation affecting cardiac tissue development. Over time, cardiac issues can lead to complications like heart failure or arrhythmias if untreated. Regular cardiac evaluations and interventions, such as surgery or medication, may be necessary to manage these conditions.
Vision problems in RFT1-CDG can include issues such as strabismus, refractive errors, or retinal abnormalities. These are caused by glycosylation defects affecting ocular tissues and neural pathways. Vision issues may worsen or stabilize over time, impacting daily activities like reading and mobility. Regular eye exams and corrective lenses or surgery can help improve vision and quality of life.
What Causes RFT1-CDG?
RFT1-CDG is caused by mutations in the RFT1 gene, which is located on chromosome 3. The RFT1 gene encodes an ER membrane protein crucial for the proper assembly of lipid-linked oligosaccharides, essential for N-glycosylation. Mutations in RFT1 disrupt the protein's structure, impairing its ability to transport lipid-linked oligosaccharides across the ER membrane. This disruption leads to incomplete glycosylation of proteins, affecting their stability and function. The deficiency in glycosylation results in ER stress and impaired protein folding, causing dysfunction in the endoplasmic reticulum. Neighboring cells and tissues are affected due to the accumulation of misfolded proteins, leading to cellular stress and apoptosis. Neuroinflammation may be triggered as a response to cellular damage, exacerbating neural dysfunction. Degeneration of white matter and other neural structures occurs due to chronic cellular stress and inflammation. Symptoms appear in a specific pattern due to the varying sensitivity of different tissues to glycosylation defects. The severity of the disease varies among patients due to differences in mutation types and residual activity of the RFT1 protein. Some patients may experience severe neurological symptoms, while others have milder presentations. The absence of epilepsy and deafness in some cases suggests variability in phenotypic expression. The role of compensatory mechanisms in certain tissues may also influence the clinical outcome. Understanding the precise molecular mechanisms can aid in developing targeted therapies. Further research is needed to explore potential treatments that can correct the glycosylation defects.
How is RFT1-CDG Diagnosed?
Typical age of diagnosis: RFT1-CDG is typically diagnosed in infancy or early childhood when clinical symptoms such as developmental delay, hypotonia, and failure to thrive become apparent. Diagnosis often follows a thorough evaluation of clinical symptoms and family history, with a focus on identifying characteristic features of congenital disorders of glycosylation.
Clinicians look for developmental delays, hypotonia, and failure to thrive. A detailed family history is important to identify any hereditary patterns. Physical examination may reveal dysmorphic features and neurological abnormalities. This step helps to narrow down the differential diagnosis towards congenital disorders of glycosylation.
Magnetic Resonance Imaging (MRI) of the brain is commonly used. Specific abnormalities such as cerebellar atrophy or white matter changes may be visible. These findings can support the diagnosis of RFT1-CDG by correlating with known neurological manifestations. Imaging helps exclude other conditions like leukodystrophies or structural brain malformations.
Serum transferrin isoelectric focusing is ordered to detect abnormal glycosylation patterns. Abnormal results show a type 1 pattern, indicating a defect in N-glycosylation. This guides further genetic testing by suggesting a congenital disorder of glycosylation. Additional tests may include liver function tests and coagulation profiles to assess systemic involvement.
The RFT1 gene is sequenced to identify pathogenic variants. Mutations such as missense or nonsense changes confirm the diagnosis of RFT1-CDG. Genetic results provide definitive diagnosis and facilitate genetic counseling for the family. They also help in assessing the risk of recurrence in future pregnancies.
RFT1-CDG Treatment Options
Mannose is a simple sugar that may help improve glycosylation. It is thought to bypass the defective glycosylation pathway in some CDG types. Clinical evidence for efficacy is limited and primarily anecdotal. Specific drugs used include oral mannose supplements. Limitations include variable patient response and potential gastrointestinal side effects.
Techniques include motor skills training and sensory integration therapy. The goal is to improve muscle tone and coordination. Sessions are typically conducted 2-3 times per week for 30-60 minutes. Measurable outcomes include improved motor milestones and enhanced quality of life. Long-term benefits may include increased independence and reduced disability.
Indicated for severe feeding difficulties and failure to thrive. The procedure involves placing a tube directly into the stomach for nutritional support. Expected benefits include improved nutritional status and growth. Surgical risks include infection and tube dislodgement. Post-operative care involves regular tube maintenance and monitoring for complications.
The team includes neurologists, geneticists, dietitians, and physical therapists. Interventions focus on optimizing nutrition, managing symptoms, and enhancing development. Psychosocial support strategies involve counseling and support groups for families. Family education covers disease management and genetic counseling. Long-term monitoring includes regular follow-ups to assess growth and development.
When to See a Doctor for RFT1-CDG
- Severe respiratory distress — this can indicate a life-threatening complication requiring immediate medical intervention.
- Unresponsive or altered mental status — this may suggest a severe neurological event or metabolic crisis.
- Sudden loss of consciousness — this could be a sign of a critical systemic failure or severe metabolic imbalance.
- Progressive muscle weakness — significant as it may indicate worsening of the condition; consult a specialist promptly.
- Hearing loss — important to address early as it can impact communication and development; seek audiological evaluation.
- Delayed developmental milestones — significant as it may indicate neurological involvement; early intervention is recommended.
- Mild fatigue — monitor energy levels and ensure adequate rest; consult a doctor if it worsens.
- Occasional headaches — track frequency and intensity; seek medical advice if they become more frequent or severe.
RFT1-CDG — Frequently Asked Questions
Is this condition hereditary?
RFT1-CDG is inherited in an autosomal recessive pattern, meaning both parents must carry a copy of the mutated gene. The probability of passing the condition to children is 25% if both parents are carriers. De novo mutations are rare but possible. Carrier status can be determined through genetic testing, which is recommended for family planning. Genetic counseling is advised to understand the risks and implications for future offspring.
What is the life expectancy for someone with this condition?
Life expectancy varies depending on the severity and age of onset. Early onset cases often have a poorer prognosis due to severe complications. Respiratory insufficiency and neurological issues are common causes of mortality. Treatment can improve quality of life and may extend survival, but it is not curative. Realistic expectations should include a focus on managing symptoms and improving daily functioning.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves a combination of clinical evaluation, biochemical tests, and genetic testing. The time from first symptoms to diagnosis can vary, often taking several months. Specialists such as geneticists and neurologists are typically involved. Delayed diagnosis is common due to the rarity and variability of symptoms. Confirmation is achieved through genetic testing identifying mutations in the RFT1 gene.
Are there any new treatments or clinical trials available?
Research is ongoing, with some promising studies focusing on gene therapy and enzyme replacement. Novel approaches are being explored, but they are still in early stages. ClinicalTrials.gov is a resource for finding relevant trials. Patients should discuss potential participation in trials with their doctor. New treatments may take several years to become widely available.
How does this condition affect daily life and activities?
RFT1-CDG can significantly impact mobility and self-care, requiring adaptive aids. Educational support is often necessary due to developmental delays. Social and emotional challenges are common, necessitating psychological support. The condition places a considerable burden on families, who may need respite care. Supportive therapies and community resources can greatly enhance quality of life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.RFT1-CDG: Absence of Epilepsy and Deafness in Two Patients with Novel Pathogenic Variants.
Quelhas D, Jaeken J, Fortuna A et al. · JIMD Rep · 2019 · PMID: 29923091
- 2.Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG.
Hirata E, Sakata KT, Dearden GI et al. · bioRxiv · 2024 · PMID: 38617304
- 3.RFT1 deficiency in three novel CDG patients.
Vleugels W, Haeuptle MA, Ng BG et al. · Hum Mutat · 2009 · PMID: 19701946
- 4.RFT1-CDG: deafness as a novel feature of congenital disorders of glycosylation.
Jaeken J, Vleugels W, Régal L et al. · J Inherit Metab Dis · 2009 · PMID: 19856127
- 5.RFT1-CDG in adult siblings with novel mutations.
Ondruskova N, Vesela K, Hansikova H et al. · Mol Genet Metab · 2012 · PMID: 23111317
- 6.A family with floppy neonates with severe respiratory insufficiency: A lethal phenotype of RFT1-CDG due to a novel mutation.
Abiramalatha T, Arunachal G, Muthusamy K et al. · Eur J Med Genet · 2019 · PMID: 30071302
- 7.An ALG12-CDG patient with a novel homozygous intronic mutation associated with low ALG12 mRNA.
Vuillaumier-Barrot S, Dupré T, Andriantsihoarana T et al. · Orphanet J Rare Dis · 2025 · PMID: 39984963
- 8.Molecular characterization of Rft1, an ER membrane protein associated with congenital disorder of glycosylation RFT1-CDG.
Hirata E, Sakata KT, Dearden GI et al. · J Biol Chem · 2024 · PMID: 39025454
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-06-17